Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 14, Pages 5333-5341Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm100623e
Keywords
-
Categories
Funding
- NIH [R01 CA134675, U24 CA92871]
- AdMeTech Foundation
Ask authors/readers for more resources
Gallium-68 is a generator-produced radionuclide for positron emission tomography (PET) that is being increasingly used for radiolabeling of tumor-targeting peptides. Compounds [Ga-68]3 and [Ga-68]6 are high-affinity urea-based inhibitors of the prostate-specific membrane antigen (PSMA) that were synthesized in decay-uncorrected yields ranging from 60% to 70% and radiochemical purities of more than 99%. Compound [Ga-68]3 demonstrated 3.78 +/- 0.90% injected dose per gram of tissue (%ID/g) within PSMA + PIP tumor at 30 min postinjection, while [Ga-68]6 showed a 2 h PSMA + PIP tumor uptake value of 3.29 +/- 0.77 %ID/g. Target (PSMA + PIP) to nontarget (PSMA - flu) ratios were 4.6 and 18.3, respectively, at those time points. Both compounds delineated tumor clearly by small animal PET. The urea series of imaging agents for PSMA can be radiolabeled with Ga-68, a cyclotron-free isotope useful for clinical PET studies, with maintenance of target specificity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available